Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Caspofungin bests fluconazole for antifungal prophylaxis in young AML patients

Key clinical point: Antifungal prophylaxis with caspofungin was better than fluconazole in children and young adults with acute myeloid leukemia (AML) at risk of invasive fungal disease.

Major finding: At 5-month follow-up, the cumulative incidence rate of probable or proven invasive fungal disease was significantly lower in the caspofungin arm (3.1%) compared with the fluconazole arm (7.2%).

Study details: A randomized clinical study of 517 children and young adults with AML.

Disclosures: The National Cancer Institute funded the study. The authors reported financial affiliations with Astellas, Celgene, Leadiant Biosciences, Merck, Nabriva Therapeutics, Novartis, Pfizer, Shire, and T2 Biosystems.


Fisher BT et al. JAMA. 2019;322(17):1673-81.